Advanced search
Publication Cover
Acta Cardiologica Volume 65, 2010 - Issue 5
Submit an article Journal homepage
7
Views
9
CrossRef citations to date
0
Altmetric
Articles

Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death

Christian PrinzDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, GermanyCorrespondence[email protected]
,
Jürgen VogtDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Thomas BitterDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Bogdan G. MunteanDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Detlef HeringDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Dieter HorstkotteDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
&
Lothar FaberDept. of Cardiology, Heart and Diabetes Centre North-Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
 show all
Pages 521-525 | Received 26 May 2010, Accepted 21 Jun 2010, Published online: 23 May 2017

References

  • Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J1958; 20: 1–18.
  • Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A descrip-tion of the disease based upon an analysis of 64 patients. Circulation 1964; 30: 3–217.
  • Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997; 350: 127–33.
  • Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemio-logy of hypertrophic cardiomyopathy-related death: revisitedin a large non-referral-based patient population. Circulation 2000; 102: 858–64.
  • Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064–75.
  • Ommen SR. HCM, SCD, ICD: an alphabet of risks, gaps, and patient counseling. Heart Rhythm 2009; 6: 998–9.
  • Behr ER, Elliott P, McKenna WJ. Role of invasive EP test-ing in the evaluation and management of hypertrophic car-diomyopathy. Card Electrophysiol Rev 2002; 6: 482–6.
  • Konno T, Chang S, Seidman JG, Seidman CE. Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 2010; Jan 30. [Epub ahead of print].
  • Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Nahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212–8.
  • Christiaans I, van Engelen K, van Langen IM, Birnie E, Bonsel GJ, Eliott PM, Wilde AA. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 2010; 12: 313–21.
  • Propescu BA, Andrade MJ, Badano LP, Fox KF, Flachs-kampf FA, Lancelotti P, Varga A, Sicari R, Evangelista A, Nikoyannopoulos P, Zamorano JL; European Association of Echocardiography, Derumeaux G, Kasprzak JD, Roelandt JR. European Association of Echocardiography recommen-dations for training, competence, and quality improvement in echocardiography. Eur J Echo cardiogr 2009; 10: 893–905.
  • Almquist AK, Montgomery JV, Haas TS, Maron BJ. Car-dioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm 2005; 2: 814–9.
  • Boriani G, Maron BJ, Shen W-K, Spirito P. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation 2004; 110: 438–42.
  • Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hyper-tmphic cardiomyopathy. N Engl J Med 2000; 342: 365–73.
  • Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bird DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation 1995; 92: 785–9.
  • Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrilla-tors and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405–12.
  • Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Man-ning WJ, Maron MS. Occurrence and frequency of arrhyth-mias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369–74.
  • Oka K, Tsujino T, Nakao S, Lee-Kawabata M, Ezumi A, Masai M, Ohyanagi M, Masuyama T. Symptomatic ven-tricular tachyarrhythmia is associated with delayed gadolin-ium enhancement in cardiac magnetic resonance imaging and with elevated plasma brain natriuretic peptide level in hypertrophic cardiomyopathy. J Cardiol 2008; 52: 146–53.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.